Compared to those in PBMCs, the proportions of TIM-3+ CD4+ T cells (p < 0.05) and PD-1+ CD8+ T cells (p < 0.01) were remarkably higher in tumor sites (Figure 3A). This evidence concerns the gene HAVCR2 and neoplasm.